Simplex Trading’s ABVC BioPharma ABVC Stock Holding History

Simplex Trading’s Portfolio ABVC Stock Details ABVC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-196	Closed	-$417	–	8933
2025 Q4	$417	Sell	196 -912	-82%	-$2.44K	﹤0.01%	8183
2025 Q3	$3K	Buy	+1,108	New	+$3.4K	﹤0.01%	8463

Other funds holding ABVC

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Simplex Trading's ABVC Position: Q1 2026 in Review

Simplex Trading sold out of ABVC BioPharma (ABVC) in Q1 2026, closing a stake of 196 shares — an estimated $417 sold.

Simplex Trading first reported a position in ABVC in Q3 2025 and held it in 2 quarters. The position peaked at $3K in Q3 2025. 13 funds tracked by Wall St. Rank hold ABVC as of Q1 2026.

Simplex Trading reported no remaining ABVC BioPharma position as of Q1 2026 after selling out during the quarter.
Simplex Trading sold 196 ABVC BioPharma shares in Q1 2026, an estimated $417.
Simplex Trading first reported a position in ABVC BioPharma in Q3 2025 and held it in 2 quarters.
Simplex Trading's ABVC BioPharma position peaked at $3K in Q3 2025.
13 funds tracked by Wall St. Rank held ABVC BioPharma as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.